Business
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Oral presentations feature phentolamine ophthalmic solution 0.75%RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cXWyemNkrNdnQ8pvyVh0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MQ--/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"text","content":"Oral presentations feature phentolamine ophthalmic solution 0.75%","length":65,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.","length":472,"tagName":"p"},{"type":"text","content":"The presentations will include data across key areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for presbyopia, and a post-hoc analysis of MIRA-2, a Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induced mydriasis, and an encore presentation of results from LYNX-2, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for visual disturbances in low light conditions in post-refractive surgery patients.","length":534,"tagName":"p"},{"type":"text","content":"Full List of Presentations at ASCRS Annual Meeting 2026","length":55,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:55%;width:55%;min-width:55%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Abstract","length":8,"tagName":"p","attribs":{}}]},{"style":"max-width:45%;width:45%;min-width:45%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Abstract Details","le...